View conference programme - The British Society for Rheumatology

More documents

Recommendations

Info

256 DOES ANTINUCLEAR ANTIBODY ELISA MISS SIGNIFICANT CONNECTIVE TISSUE DISEASE ? AYN Lim, G Maguire, G Wood, DS Kumararatne, JSH Gaston. 1 Department of Rheumatology, Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 Department of Clinical Immunology, Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 3 Department of Clinical Immunology, Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 4 Department of Clinical Immunology, Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 5 Department of Rheumatology, Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom 257 DOUBLE BLIND, CROSSOVER, RANDOMISED TRIAL COMPARING LOW MOLECULAR WEIGHT HEPARIN VERSUS PLACEBO IN THE TREATMENT OF CHRONIC HEADACHE IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES. G Sanna 1 , MJ Cuadrado 2 , M Sharief 3 , MA Khamashta 4 , GRV Hughes 5 . 1 Rheumatology, Homerton University Hospital, London, England, United Kingdom; 2 Lupus Rearch Unit, St. Thomas’ Hospital, London, England, United Kingdom; 3 Neurology, St. Thomas’ Hospital, London, England, United Kingdom; 4 Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom; 5 Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom 258 THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS. S Khanna 1 , H Pal 2 , RM Pandey 3 , R Handa 4 . 1 All India Institute of Medical Sciences, New Delhi, India; 2 Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India; 3 Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India; 4 Department of Medicine, All India Institute of Medical Sciences, New Delhi, India 259 PREVALENCE OF ANTITHYROID ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME. P Harrison 1 , GT Swana 2 , MR Swana 3 , ML Bertolaccini 1 , MA Khamashta 1 , DP D’Cruz 1 , GRV Hughes 1 . 1 Lupus Research Unit, The Rayne Institute, London, United Kingdom; 2 Immunology Department, St.Thomas’ Hospital, London, United Kingdom; 3 Immunology Department, University College London Hospital, London, United Kingdom 260 ATYPICAL CO-LOCALISATION OF CD45 AND LYN TO LIPID RAFT SIGNALLING DOMAINS CORRELATES WITH B-LYMPHOCYTE HYPER RESPONSIVENESS IN PATIENTS WITH LUPUS. F Flores-Borja 1 , PS Kabouridis 1 , E Jury 2 , D Isenberg 2 , RA Mageed 1 . 1 Bone and Joint Research Unit, St Bartholomew’s and The Royal London, Queen Mary School of Medicine, London, United Kingdom; 2 Centre for Rheumatology, University College London, London, United Kingdom 261 A SINGLE MUTATION OF AN ARGININE RESIDUE ALTERS THE BINDING AFFINITY OF A HUMAN MONOCLONAL ANTIBODY TO DIFFERENT ANTIGENS. N Lambrianides 1,2 , A Rahman 1,2 , L Mason 2 , D Latchman 1 , D Isenberg 2 . 1 Medical Molecular Biology Unit, Institute of Child Health, University College London, London, United Kingdom; 2 Centre for Rheumatology, University College London, London, United Kingdom 262 ANTIBODIES AGAINST OXIDISED THE COMPLEX LOW DENSITY LIPOPROTEIN-BETA - 2 - G LYCOPROTEIN-I MAY HAVE A PRO- ATHEROGENIC ROLE IN PRIMARY ANTIPHOSPHOLIPID SYNDROME. PRJ Ames 1 , J Delgado-Alves 2 , D Lopez 3 , L Lopez 3 , E Matsuura 4 , A Margarita 5 , L Iannaccone 5 , V Brancaccio 5 . 1 Academic Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom; 2 Department of Internal Medicine, Curry Cabral Hospital, Lisbon, Portugal; 3 Science and Research, Corgenix Ltd, Denver, CO, United States; 4 Department of Biochemistry, Okayama School of Medicine, Okayama, Japan; 5 Angiohaemostasis Unit, Ospedale A. Cardarelli, Naples, Italy 263 STABLE TRANSFECTION OF CHO CELLS TO EXPRESS WHOLE HUMAN IgG ANTIPHOSPHOLIPID ANTIBODIES. N Lambrianides 1,2 , I Giles 1,2 , D Latchman 1 , D Isenberg 2 , A Rahman 1,2 . 1 Medical Molecular Biology Unit, Institute of Child Health, University College London, London, United Kingdom; 2 Centre for Rheumatology, University College London, London, United Kingdom 62
264 TREATMENT OF REFRACTORY LUPUS NEPHRITIS WITH B LYMPHOCYTE DEPLETION. MJ Leandro, MR Ehrenstein, JCW Edwards, J Manson, G Cambridge, DA Isenberg. Centre for Rheumatology, University College London, London, United Kingdom VASCULITIS (265 – 270) 265 PREDICING TEMPORAL ARTERITIS IN PEOPLE WITH PRESENTING POLYMYALGIC SYMPTOMS. CT Pease, G Haugeberg, AW Morgan, BB Bhakta. Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom 266 PREDICTING DURATION OF ORAL PREDNISOLONE TREATMENT IN PEOPLE WITH POLYMYALGIA RHEUMATICA. CT Pease, G Haugeberg, BB Bhakta. 1 Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 2 Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 3 Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom 267 THE PREVALENCE AND ASSOCIATIONS OF AN ABNORMAL ANKLE-BRACHIAL PRESSURE INDEX IN SYSTEMIC VASCULITIS: A PILOT STUDY. M Mora, C Noronha, B Grima, MA Baron, M Liz, MA Khamashta, GRV Hughes, DP D’Cruz. The Lupus Research Unit, St Thomas’ Hospital, London, United Kingdom 268 DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE. JS McLaren, CJ Hall, RA Luqmani. Rheumatic Diseases Unit, University of Edinburgh, Edinburgh, United Kingdom 269 WEGENER’S GRANULOMATOSIS: COMPARISON OF OUTCOME IN PATIENTS TREATED WITH LOW DOSE IV CYCLOPHOSPHAMIDE, ORAL CYCLOPHOSPHAMIDE OR OTHER CYTOTOXIC AGENTS. AN Bennett, C Noronha, JD Rees, DP D’Cruz, GRV Hughes. Lupus Research Unit, St Thomas’ Hospital, London, United Kingdom 270 THE PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODIES IN A COHORT OF PATIENTS WITH SYSTEMIC VASCULITIS. J Rees, S Lanca, PV Marques, JA Gómez-Puerta, MA Khamashta, DP D’Cruz, GRV Hughes. The Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, United Kingdom PAEDIATRIC RHEUMATOLOGY (271 – 278) 271 SUBGROUP CLASSIFICATION OF CHILDREN WITH JIA USING THE ILAR SCHEME DOES NOT CHANGE OVER 12 MONTHS OF OBSERVATION. N Adib 1 , J Davidson 2 , E Baildam 3 , M Lay 1 , A Silman 1 , W Thomson 1 . 1 ARC Epidemiology Unit, Manchester University Medical School, Manchester, United Kingdom; 2 Rheumatology, Royal Liverpool Children’s Hospital, Liverpool, United Kingdom; 3 Rheumatology, Royal Manchester Childrens Hospital, Manchester, United Kingdom 272 CONFIRMATION OF ASSOCIATION OF HLA-DRB1*13 WITH UVEITIS IN JUVENILE IDIOPATHIC ARTHRITIS. E Zeggini 1 , W Thomson 2 , P Wordsworth 3 , MA Hall 3 , JC Packham 4 . 1 Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United Kingdom; 2 ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 3 Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom; 4 Staffordshire Rheumatology Centre, Haywood Hospital, Stoke on Trent, United Kingdom 63
Page 1:
BSR 2004 Annual Meeting A joint mee
Page 6 and 7:
BSR Annual Meeting & BHPR Spring Me
Page 8 and 9:
• Spondyloarthritis Harris 1 Conv
Page 10 and 11:
16:00 - 16:30 Tea Cromdale Hall 16:
Page 12 and 13:
11:30 - 13:00 BSR: Interface of rhe
Page 14 and 15: 11:45 Collagen III and V mutations
Page 16 and 17: • EMG / NCS Carrick 3 Convenor: I
Page 18 and 19: Pfizer Pain Management: Hot Topics
Page 20 and 21: • Recent advances in spondyloarth
Page 22 and 23: Rheumatoid arthritis pathogenesis F
Page 24 and 25: This has proved to be a huge succes
Page 26 and 27: Additional Meetings Please note tha
Page 28 and 29: OP9 ASSOCIATION BETWEEN DIETARY CAR
Page 30 and 31: OP24 A RANDOMISED CONTROLLED TRIAL
Page 32 and 33: Concurrent Oral Sessions Thursday 2
Page 34 and 35: OP54 OX40L, BUT NOT OX40, IS ASSOCI
Page 36 and 37: BHPR Oral Presentations Friday 23 A
Page 38 and 39: 17 POLYMORPHISMS OF WISP3 AND SUSCE
Page 40 and 41: 33 FATAL EXACERBATION OF RHEUMATOID
Page 42 and 43: 51 UNDERSTANDING NON-RESPONSE TO IN
Page 44 and 45: 71 METHOTREXATE MONITORING: A COUNT
Page 46 and 47: BONE MINERAL DENSITY (88 - 104) 88
Page 48 and 49: OSTEOARTHRITIS (108 - 132) 108 PREV
Page 50 and 51: 123 EFFECT OF LUMIRACOXIB ON BLOOD
Page 52 and 53: 143 THE EPIDEMIOLOGY OF ADHESIVE CA
Page 54 and 55: 159 A SURVEY OF LONG-TERM NSAID USE
Page 56 and 57: 180 DEGREE OF FUNCTIONAL DISABILITY
Page 58 and 59: 200 CAUSES OF MUSCULOSKELETAL CHEST
Page 60 and 61: SCLERODERMA (216 - 233) 216 OXIDISE
Page 62 and 63: SJÖGREN’S SYNDROME (236 - 239) 2
Page 66 and 67: 273 A USER PERSPECTIVE OF THE RHEUM
Page 68 and 69: Poster Viewing Session 3 Friday 23
Page 70 and 71: 314 CHANGE IN PATIENT-ASSESSED HEAL
Page 72 and 73: MISCELLANEOUS RHEUMATIC DISEASE (33
Page 74 and 75: 350 ARE FLEXION/EXTENSION VIEWS OF
Page 76 and 77: 369 COMORBIDITY AMONG PATIENTS WITH
Page 78 and 79: BHPR (387 - 437) 387 A LIFESTYLE MA
Page 80 and 81: 406 PHYSIOTHERAPISTS’ PERCEIVED P
Page 82 and 83: 428 EVALUATION OF AN IN-PATIENT JOI
Page 84 and 85: Exhibition Floor Plan 82
Page 86 and 87: Exhibitor Product Listings 4S Dawn
Page 88 and 89: Janssen-Cilag Janssen-Cilag Limited
Page 90 and 91: RCN The Royal College of Nursing (R
show all

View conference programme - The British Society for Rheumatology

Create successful ePaper yourself

Delete template?

Save as template?